The strong correlation between CEACAM1 expression levels and the BCR signature in MCL tumors (Fig. 3g), and its relationship to ibrutinib responsiveness in MCL and MZL cell lines (Fig. 3h), suggests a potential utility of CEACAM1 as a biomarker of ibrutinib therapy in these lymphomas. This evidence concerns the gene CEACAM1 and marginal zone lymphoma.